Why the MARS2 Trial Does Not Mean the End of All Mesothelioma Surgery
As contemporary selection criteria were not applied in MARS2, its conclusions cannot be universally applied to all those with PM. Together with the favourable postoperative survival in this selected group, we suggest that there is still scope for a further trial of surgery in early-stage epithelioid mesothelioma.
Authors
- Andrea Billè (ORCID: https://orcid.org/0000-0003-4709-4174)
- David A. Waller (ORCID: https://orcid.org/0009-0002-3058-496X)
- Sara Tenconi (ORCID: https://orcid.org/0009-0006-7005-8867)
- Laura Socci
- Luigi Ventura (ORCID: https://orcid.org/0000-0002-4023-0578)
- Rocco Bilancia (ORCID: https://orcid.org/0009-0004-4308-5064)
Institutions
- Guy's Hospital (GB)
- St Bartholomew's Hospital (GB)
- Northern General Hospital (GB)
- Golden Jubilee National Hospital (GB)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3390/cancers17050724
- Citations
- 2
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.04